Coordinated action is required to ensure that people with type 2 diabetes, cardiovascular disease, heart failure, or chronic kidney disease are treated appropriately with an SGLT-2 inhibitor or GLP-1RA. The gene discussed is SLC5A2; the disease is heart failure.